The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)
Barry M. Brenner
,
Mark E. Cooper
,
Dick de Zeeuw
,
Barry M. Brenner
,
Mark E. Cooper
,
Dick de Zeeuw
,
Jean‐Pierre Grünfeld
,
William F. Keane
,
Kiyoshi Kurokawa
,
Janet B. McGill
,
William E. Mitch
,
Hans Henrik Parving
,
Giuseppe Remuzzi
,
Arthur Barcelos Ribeiro
,
Mark Schluchter
,
Duane Snavely
,
Zhongxin Zhang
,
Roger L. Simpson
,
Denise Ramjit
,
Shahnaz Shahinfar
,
RENAAL Study Investigators
2000
Journal of the Renin-Angiotensin-Aldosterone System
138 citations